WO2010062038A3 - Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant - Google Patents

Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant Download PDF

Info

Publication number
WO2010062038A3
WO2010062038A3 PCT/KR2009/006050 KR2009006050W WO2010062038A3 WO 2010062038 A3 WO2010062038 A3 WO 2010062038A3 KR 2009006050 W KR2009006050 W KR 2009006050W WO 2010062038 A3 WO2010062038 A3 WO 2010062038A3
Authority
WO
WIPO (PCT)
Prior art keywords
isomer
tyrosine kinase
pharmaceutical composition
composition containing
same
Prior art date
Application number
PCT/KR2009/006050
Other languages
English (en)
Korean (ko)
Other versions
WO2010062038A2 (fr
Inventor
양범석
김선영
조종운
이향숙
우성호
박태교
김용주
김승태
이홍범
Original Assignee
한국과학기술연구원
주식회사 레고켐 바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술연구원, 주식회사 레고켐 바이오사이언스 filed Critical 한국과학기술연구원
Publication of WO2010062038A2 publication Critical patent/WO2010062038A2/fr
Publication of WO2010062038A3 publication Critical patent/WO2010062038A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Abstract

La présente invention concerne un composé exprimé dans la formule chimique 1, un isomère de celui-ci ou un sel de celui-ci pharmaceutiquement acceptable. Le composé exprimé dans la formule chimique 1 inhibe l'activité de la tyrosine kinase du récepteur 1 à domaine discoïdine (DDR1) et du récepteur 2 à domaine discoïdine (DDR2), et peut-être ainsi utilisé valablement dans la prévention ou le traitement de maladies telles que le cancer, la cirrhose du foie, l'artériosclérose, l'arthrite rhumatoïde, l'ostéoarthrite et autre, qui sont connues pour être provoquées principalement par une activation excessive du récepteur 1 à domaine discoïdine et du récepteur 2 à domaine discoïdine.
PCT/KR2009/006050 2008-11-27 2009-10-20 Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant WO2010062038A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0118850 2008-11-27
KR1020080118850A KR101126736B1 (ko) 2008-11-27 2008-11-27 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2010062038A2 WO2010062038A2 (fr) 2010-06-03
WO2010062038A3 true WO2010062038A3 (fr) 2010-07-22

Family

ID=42226201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006050 WO2010062038A2 (fr) 2008-11-27 2009-10-20 Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant

Country Status (2)

Country Link
KR (1) KR101126736B1 (fr)
WO (1) WO2010062038A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647586T3 (es) * 2010-05-26 2017-12-22 Korea Institute Of Science And Technology Compuesto antiinflamatorio que tiene actividad inhibidora contra múltiples tirosina cinasas, y composición farmacéutica que contiene el mismo
BR112013006016A2 (pt) * 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
CN103087077B (zh) * 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
US20140286965A1 (en) 2011-11-07 2014-09-25 Inserm Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
CN103360407B (zh) * 2012-04-10 2016-06-22 上海希迈医药科技有限公司 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN105829285A (zh) * 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
KR101540051B1 (ko) * 2013-11-27 2015-07-28 한국과학기술연구원 피부 노화 방지 또는 피부 상태 개선용 조성물
TWI676482B (zh) 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
MX2022014295A (es) 2020-05-25 2022-12-07 Chiesi Farm Spa Derivados de la bencilamina como inhibidores de los receptores del dominio de discoidina.
EP4032896A1 (fr) 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidinones en tant qu'inhibiteurs de ddr1/2 et leurs utilisations thérapeutiques
TW202400563A (zh) * 2022-04-25 2024-01-01 日商日本新藥股份有限公司 作為ddr1激酶抑制劑之化合物及醫藥

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
WO1997013771A1 (fr) * 1995-10-11 1997-04-17 Glaxo Group Limited Composes hetero-aromatiques bicycliques utilises comme inhibiteurs de proteine tyrosine kinase
KR20010031908A (ko) * 1997-11-11 2001-04-16 실버스타인 아써 에이. 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
US20040019065A1 (en) * 2002-03-01 2004-01-29 Romines William Henry Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040142A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
WO1997013771A1 (fr) * 1995-10-11 1997-04-17 Glaxo Group Limited Composes hetero-aromatiques bicycliques utilises comme inhibiteurs de proteine tyrosine kinase
KR20010031908A (ko) * 1997-11-11 2001-04-16 실버스타인 아써 에이. 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
US20040019065A1 (en) * 2002-03-01 2004-01-29 Romines William Henry Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use

Also Published As

Publication number Publication date
KR20100060300A (ko) 2010-06-07
KR101126736B1 (ko) 2012-04-12
WO2010062038A2 (fr) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2010062038A2 (fr) Composé inhibiteur de la tyrosine kinase, isomère ou sel de celui-ci acceptable pharmaceutiquement,et composition pharmaceutique le contenant
WO2006123113A3 (fr) Composes chimiques
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2006138660A3 (fr) Inhibiteurs de la sphingosine kinase
MX2009013077A (es) Derivados dde benzoxazolona.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
UA94622C2 (en) Kinase innhibitor
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2011052923A3 (fr) Nouveaux composés d'indole 1,6-disubstitués utilisés en tant qu'inhibiteurs des protéines kinases
EP2134346A4 (fr) Inhibiteurs de janus kinases et/ou protéine kinase-1 dépendant de la 3-phosphoinositide
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
WO2008118391A3 (fr) Composés qui modulent l'activité hsp90
WO2010017545A3 (fr) Composés de triazole qui modulent l'activité hsp90
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
NZ623069A (en) Heat shock protein binding compounds, compositions, and methods for making and using same
WO2008011557A3 (fr) Inhibiteurs hétéroaryliques de la kinase rho
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MY148634A (en) Pyridazinone derivatives
WO2007049041A8 (fr) Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.08.11 AND 02.09.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09829245

Country of ref document: EP

Kind code of ref document: A2